Please login to the form below

ledipasvir

This page shows the latest ledipasvir news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

The EC also approved an extension for Harvoni (ledipasvir/sofobuvir), - which was previously authorised to treat adults with chronic HCV genotypes 1, 3, 4, 5, or 6 - and will now include

Latest news

Merck & Co pulls out of hepatitis C R&D as market shrinks

In the same period, Gilead’s HCV portfolio of Harvoni (sofosbuvir/ledipasvir), Epclusa (sofosbuvir/velpatasvir) and Sovaldi (sofosbuvir) brought in $5.44bn, down from around $8.3bn in the first half
Gilead makes $11.9bn play for CAR-T specialist Kite

Gilead's deal comes as it faces a sharp slowdown in sales of its HCV therapies - led by Harvoni (sofosbuvir and ledipasvir) and Sovaldi (sofosbuvir) - which has led investors to call
Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.
Samsung Bioepis wins CHMP nod for second Humira biosimilar

Both were reviewed under the accelerated assessment protocol because despite the robust efficacy of current drugs such as Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira (ombitasvir/paritaprevir/ritonavir and
Two new hepatitis C therapies fast-tracked in Europe

Sofosbuvir and velpatasvir are the two active ingredients in Gilead's recently-approved two-drug HCV combination Epclusa, as a successor to its massively successful Harvoni (sofosbuvir/ledipasvir) but with activity

More from news
Approximately 4 fully matching, plus 62 partially matching documents found.

Latest Intelligence

AbbVie: New firm, new thinking

Gilead Sciences has emerged as the leader in this field with Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir), both of which have already made billions of dollars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer: Great salary and bebefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Scientific Director: Great salary and bebefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Programme Executive: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...